THYMIC CARCINOMAS DIAGNOSED AT THE PATHOLOGY DEPARTMENT AT JRA HOSPITAL
DOI:
https://doi.org/10.53555/bp.v8i12.2121Keywords:
Carcinoma, Madagascar, Thymus, Thymic Epithelial TumourAbstract
INTRODUCTION
Thymic epithelial tumours are rare pathologies but represent 20% of mediastinum tumours [1] and are the first cause of anterior mediastinal mass (35 to 50% of cases). According to World Health Organization (WHO) classification in 2004, thymic epithelial tumors are divided on three types: thymomas (80% of cases), thymic carcinomas and neuroendocrine tumours (5%) [2, 3]. Thymic carcinomas have an incidence of 0.2 to 0.5 per million people [4]. Itrepresent 5% of all malignant thymic tumours and 15% of thymic epithelial tumours. These are aggressive tumours [1, 5]. The overall survival rate at 5 years is about 30 to 50%, and it is less than 20% between 5 and 10 years [6, 7]. The aim of our study is to describe the epidemiological and histopathologicalfeatures of thymic carcinomas, diagnosed at the Pathology Department, with a review of the literature.
Materials and method
This is a retrospective and descriptive study of thymic carcinomas diagnosed at the Pathology Departmentat JRAUniversity Hospital, during 10 years from January 2010 to December 2019.
Downloads
References
PA Thomas, MJ Payan-Defais. (2010) Tumeurs épithéliales thymiques. Revue de Pneumologie clinique ; 66 : 41—51.
Marx A, Ströbel P, Badve SS. (2014) ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J ThoracOncol; 9:596–611.
Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. (eds.), Lyon: International Agency for Research on Cancer (IARC) Press; 2004.
Girard N, Maury JM, Chalabreysse L, Besse B, Rythmic .(2016) Tumeursthymiques. EMC – Pneumologie;13(3):1-15
Giuseppe Giaccone, Chul Kim, Jillian Thompson, Colleen McGuire, BhaskarKallakury, Joeffrey J Chahine, et al. (2018) Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol; 19: 347–55
Yu Yang, Xing-Wen Fan, Hong-Bing Wang, Yin Xu, Dou-Dou Li, Kai-Liang Wu. (2017) Stage IVbthymic carcinoma: patients with lymph node metastases have better prognoses than those with hematogenous metastases. BMC Cancer 17:217
Chun-Hsiang Hsu, Chan JK, Yin C-H, Lee C-C, Chern C-U, Liao C-I. (2019) Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States. PLoS ONE, 14(12): 1-13
C. Le Péchoux, M. Mahé, J.-J. Bretel, E. Roberti, P. Ruffié. (2005) Tumeurs épithéliales thymiques. Cancer/Radiothérapie 9 351–357
S. Suster, J. Rosai. ThymicCarcinom. (1991) AClinicopathologic Study of 60 Cases. CANCER ; 67 : 1025-1032.
A. Ayadi-Kaddoura, D. Bachaa, B. Smatib, T. Kilani, F. El Mezni. (2009) Carcinomes thymiques primitifs : à propos de trois cas avec revue de la littérature. Revue de Pneumologie clinique65, 113—117.
Cesar A. Moran, Saul Suster. ((2008)) Thymic Carcinoma: Current Concepts and Histologic Features. HematolOncolClin N Am 22 393–407
Marx A, Rieker R, Toker A, Langer F, Strobel P. (2011) Thymic carcinoma: is it a separate entity? From molecular to clinical evidence. ThoracSurgClin.; 21:25–31.
Ricardo V. Lloyd, Lori A. Erickson. (2015) Neuroendocrine and Paracrine Systems. inSternberg’s Diagnostic Surgical Pathology. Sixth Edition. Wolters Kluwer; 1871 – 78.
Wolfgang Jungraithmayr, Didier Schneiter, Alex Soltermann, Thomas Frauenfelder, Walter Weder.(2016) Diagnostic et traitement du carcinome thymique Forum Médical Suisse;16(47):1019–1025
Lara Chalabreysse, Vincent Thomas De Montpreville, Anne De Muret, Véronique Hofman, Sylvie Lantuejoul et al. (2014) Rythmic-Pathologie : le groupe français de relecture des tumeurs épithéliales thymiques du réseau clinique Rythmic. Annales de pathologie ; 34 : 87—91.
W. Jacot, X. Quantin, J.-L. Pujol. (2006) Treatment of epithelial thymictumours: towards a multidisciplinary management. Rev Mal Respir; 23 : 3S35-3S46
Weissferdt A, Moran CA. (2014) Immunohistochemistry in the Diagnosis of Thymic Epithelial Neoplasms. ApplImmunohistochemMolMorphol; 22:479–87.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Journal For Research In Biology & Pharmacy
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In consideration of the journal, Green Publication taking action in reviewing and editing our manuscript, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to the Editorial Office of the Green Publication in the event that such work is published in the journal. Such conveyance covers any product that may derive from the published journal, whether print or electronic. Green Publication shall have the right to register copyright to the Article in its name as claimant, whether separately
or as part of the journal issue or other medium in which the Article is included.
By signing this Agreement, the author(s), and in the case of a Work Made For Hire, the employer, jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere, and is not being considered for publication elsewhere in any form, except as provided herein. Each author’s signature should appear below. The signing author(s) (and, in
